Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Non-Current Debt (2016 - 2025)

IGC Pharma (IGC) has disclosed Non-Current Debt for 14 consecutive years, with $132000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 2.22% to $132000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $132000.0, a 2.22% decrease, with the full-year FY2025 number at $134000.0, down 2.19% from a year prior.
  • Non-Current Debt was $132000.0 for Q3 2025 at IGC Pharma, down from $133000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $276000.0 in Q1 2021 to a low of $132000.0 in Q3 2025.
  • A 5-year average of $146473.7 and a median of $140000.0 in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: crashed 76.67% in 2021, then fell 2.08% in 2023.
  • IGC Pharma's Non-Current Debt stood at $145000.0 in 2021, then fell by 2.76% to $141000.0 in 2022, then fell by 2.13% to $138000.0 in 2023, then dropped by 2.9% to $134000.0 in 2024, then dropped by 1.49% to $132000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Non-Current Debt are $132000.0 (Q3 2025), $133000.0 (Q2 2025), and $134000.0 (Q1 2025).